The post JPMorgan Considers Bitcoin For Institutional Clients appeared on BitcoinEthereumNews.com. JPMorgan Chase is weighing whether to offer bitcoin trading servicesThe post JPMorgan Considers Bitcoin For Institutional Clients appeared on BitcoinEthereumNews.com. JPMorgan Chase is weighing whether to offer bitcoin trading services

JPMorgan Considers Bitcoin For Institutional Clients

JPMorgan Chase is weighing whether to offer bitcoin trading services to institutional clients, according to a Bloomberg report citing a person familiar with the matter.

The largest U.S. bank by assets is assessing potential products that could include spot bitcoin trading and derivatives within its markets division. The discussions remain preliminary, and no decision has been made to launch the services, the report said.

Any move would depend on several factors, including client demand, internal risk assessments, and whether the bank can structure offerings that fit within existing regulatory frameworks. JPMorgan has not commented publicly on the report.

The internal review reflects growing interest among large investors for access to digital asset markets through established financial institutions. Hedge funds, asset managers, and pension funds increasingly seek trading venues that align with their compliance, governance, and execution requirements. 

Institutional clients often prioritize balance sheet strength, operational resilience, and regulated market access when trading new asset classes. For some firms, those requirements narrow the range of acceptable counterparties, even as liquidity in crypto markets has expanded.

Scott Lucas, who leads digital assets for JPMorgan’s markets division, said in an interview earlier this year that the bank planned to pursue trading activities tied to digital assets but did not intend to provide custody services. That approach would mirror how some banks engage with commodities and other non-traditional assets.

JPMorgan analysts also recently said that bitcoin appears cheap relative to gold after a sharp October sell-off, with strategists pointing to upside potential toward $170,000.

JPMorgan is pivoting on bitcoin

The bank’s interest comes as regulatory conditions in the U.S. begin to shift. Market participants expect progress on federal digital asset legislation, while banking regulators have recently clarified that federally chartered banks may act as intermediaries in certain crypto-related activities. 

JPMorgan has expanded its engagement with blockchain technology over the past several years without embracing cryptocurrencies as a core asset class. The bank has worked on tokenization, on-chain settlement, and distributed ledger infrastructure. 

Earlier this year, it arranged the issuance and settlement of a short-term bond for Galaxy Digital using the Solana network.

The firm has also said it plans to allow institutional clients to use bitcoin and ether as collateral in lending arrangements, a step that acknowledges demand without committing to proprietary exposure.

A move into bitcoin trading would mark a further shift in tone for JPMorgan and its chief executive, Jamie Dimon, who has long criticized bitcoin while maintaining that clients should be free to make their own investment decisions.

JPMorgan would not be alone among global banks reassessing crypto markets. Standard Chartered has launched spot trading for bitcoin and ether through its U.K. operations, while Goldman Sachs continues to operate a crypto derivatives desk. 

Source: https://bitcoinmagazine.com/news/jpmorgan-considers-bitcoin-for-clients

Market Opportunity
Union Logo
Union Price(U)
$0,000878
$0,000878$0,000878
-%1,67
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03